GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (4)
  • Oka, Takashi  (4)
Material
Publisher
  • American Association for Cancer Research (AACR)  (4)
Language
Years
Subjects(RVK)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 3132-3132
    Abstract: HTLV-1 causes ATLL in 3-5% of infected individuals after a long latent period of 40 to 60 years. ATLL is divided into four stages: namely, smoldering, chronic, lymphoma and acute types. The smoldering and chronic types are indolent, but the acute and lymphoma types are aggressive ATLL characterized by resistance to chemotherapy and a poor prognosis. Such a long latent period suggests that a multi-step leukemogenic/lymphomagenic mechanism is involved in the development of ATLL, although the critical events in the progression have not been characterized. To determine whether epigenetic abnormalities are playing the important role in the progression of ATLL, we analyzed the methylation profiles, showing that number of CpG island methylated genes increased with disease progression and aberrant hyper-methylation in specific genes was detected even in HTLV-1 carriers and correlated with progression to ATLL. The CpG island methylator phenotype (CIMP) was observed most frequently in lymphoma type ATLL and was also closely associated with the progression and crisis of ATLL. The high number of methylated genes and increase of CIMP incidence were shown to be unfavorable prognostic factors and correlated with a shorter overall survival with the Kaplan-Meyer analysis. Dynamic changes of aberrant DNA methylation status in the specific genes were observed during the progression of an ATLL patient. The present findings strongly suggest that the multi-step accumulation of aberrant CpG methylation in specific target genes and the presence of CIMP are deeply involved in the initiation and progression of ATLL not only epidemiologically but also in the clinical course of a specific ATLL patient. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3132. doi:1538-7445.AM2012-3132
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Research Vol. 70, No. 8_Supplement ( 2010-04-15), p. LB-246-LB-246
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. LB-246-LB-246
    Abstract: Background: MicroRNAs (miRNAs) are small non-cording RNAs (20-23 nucleotides) that negatively regulate gene expression at post-transcriptional level by interacting with 3′UTRs of their target mRNAs. Aberrant expression of miRNAs in cancer indicates that miRNAs play key roles in human cancers acting as either oncogenes or tumor suppressor genes depending on their targets. The miR-17-92 cluster, including miR-17-5p, -17-3p, -18a, -19a, -20a, -19b and -92-1, located on C13orf25 is well known as oncogenic miRNA, which is overexpressed in lung cancer, malignant lymphoma and breast cancer. However, few data have been collected about the targets of miRNAs, including miR-17-92 cluster, and their roles in tumorigenesis. By using a proteomic approach, we identify novel direct targets of miR-19a. Methods and Results: MiR-17-92 expression profiling was performed in a subset of 32 of cancer cell lines by TanqMan Real-time PCR, and MCF-7 breast cancer cell line was identified as a miR-17-92 cluster overexpressed cell line. To detect candidate target proteins for miR-17-92 cluster, we transfected MCF-7 cell with antisense oligonucleotides against miR-19a, -20a and -92-1 and then performed two-dimensional protein electrophoresis (2-DE) and differential display analysis in protein extracts of MCF-7 which was knocked down of endogenous miR-17-92 by antisense oligonucleotides. Of the 1455 defined valid protein spots, 146 distinct proteins changed 1.5-fold their expression. 135 proteins were identified as candidate target proteins for miR-17-92 cluster by LC-MS/MS. To determine direct targets of miR-17-92, bioinformatics analysis, luciferase assay and western blotting analysis were performed as validation studies. Conclusions: Our results of exhaustive analysis revealed significant differences in the proteomic profile between anti-miR-LNA treated and non-treated MCF-7 breast cancer cell line. Among these candidate target proteins of miR17-92 cluster, we identified novel direct target of miR-19a. To better evaluate the role of miR-19a and the target gene, further studies of gene function are being performed now. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-246.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 1034-1034
    Abstract: Polycomb group (PcG) proteins are involved in regulation of hematopoiesis, which include two main members Ezh2 and Bmi-1. Reports on their expression levels in different subtypes of malignant lymphoma and role in lymphomagensis and tumor progression are rather limited. To address this issue, we analyzed a total of 197 patient samples including 10 samples of Hodgkin lymphoma (HL), 109 of B-cell lymphoma (BCL) and 78 of T-cell lymphoma (TCL) by immunohistochemistry. The results showed overall expression in HL, BCL and TCL to be 90%, 56.9% and 84.6% for Ezh2 and 90%, 82.5% and 84.6% for Bmi-1 respectively. Among BCL, highest Ezh2 positivity was seen in Burkitt's lymphoma (BL) followed by high-grade follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). In TCL, Ezh2 expression was observed in all subtypes and seemed more homogenous. Difference in its expression between aggressive and indolent subtypes of BCL was statistically significant (p= 0.000∼0.010). On the other hand, Bmi-1 was rather more consistently expressed in both BCL and TCL up to 100% in 7 subtypes. Difference in its expression between aggressive and indolent subtypes was statistically insignificant. Ki67 showed strong positive correlation with Ezh2 in BCL (Correlation coefficient (Co) =0.983, p= 0.000) and moderate correlation in TCL (Co=0 .629, p= 0.000). This correlation could not be detected in case of Bmi1. These data suggest that out of the two Polycomb group (PcG) proteins, only Ezh2 correlates with tumor proliferation and signals a more aggressive nature. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1034. doi:1538-7445.AM2012-1034
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Clinical Cancer Research, American Association for Cancer Research (AACR), Vol. 11, No. 20 ( 2005-10-15), p. 7255-7263
    Abstract: Purpose: Bcl-2 is a model apoptosis suppressor postulated to promote tumorigenesis. Recently, it has been reported that Bcl-2 undergoes phosphoregulation of its Ser70 to substantially alter its molecular function. Previous studies further suggest that such phospho-Bcl-2 regulation may influence tumor progression in colorectal and other cancers; however, phosphorylation status of the Ser70 of Bcl-2 (pSer70) in vivo in tumors remains obscure. To elucidate this question that may suggest the biological role, we molecularly screened a panel of human colorectal adenomas and adenocarcinomas for endogenous expression of pSer70 Bcl-2. Experimental Design: An antibody specific against pSer70 Bcl-2 was generated for thorough immunohistochemical examination of paraffin-embedded tumor specimens, allowing detection of the endogenously expressed antigen among a range of Bcl-2-positive colorectal neoplasms, including 75 tubular adenomas, 114 adenocarcinomas, and 15 cases of cancer in adenomas. Results: Loss of pSer70 Bcl-2 expression was observed in adenocarcinomas in a differentiation-dependent manner (positivities: well differentiated 63%, moderately differentiated 52%, and poorly differentiated 12%), whereas tubular adenomas maintained their expression (positivity 88%). Interestingly, an inverse correlation was found between expression of pSer70 Bcl-2 and Ki-67 antigen in those cases of cancer in adenoma (P & lt; 0.01). It was further observed that loss of pSer70 Bcl-2 expression was associated with significantly shorter survival (P & lt; 0.05) and correlated with clinical stages and lymph node metastasis (P & lt; 0.05 and P & lt; 0.05, respectively). Conclusions: Loss of pSer70 Bcl-2 expression is closely linked to biological aggressiveness in colorectal tumors and represents a statistically significant molecular index for prognosis of patients with these tumors.
    Type of Medium: Online Resource
    ISSN: 1078-0432 , 1557-3265
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2005
    detail.hit.zdb_id: 1225457-5
    detail.hit.zdb_id: 2036787-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...